Bixiye
QP76-21 Commercial and MHCP Pharmacy Benefit Exclusion for Uptravi®
Taariikhda uu dhaqangalayo barnaamijka: Okt 13, 2021
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 1521 - 1530 ee natiijooyinka 3613
Bixiye
QP77-21 Commercial Pharmacy Benefit Update – Revised Drug-Related Prior Authorization (PA) Requirement Notification – Effective December 1, 2021
Taariikhda uu dhaqangalayo barnaamijka: Okt 13, 2021
Bixiye
QP78-21 Commercial Pharmacy Benefit Update – New Drug-Related Quantity Limit (QL) Criteria: Stromectol® (ivermectin)
Taariikhda uu dhaqangalayo barnaamijka: Okt 13, 2021
Bixiye
QP79-21 New Availity Appeal Portal Available to Create, Submit and Inquire on Post Service Claim Appeals
Taariikhda uu dhaqangalayo barnaamijka: Okt 13, 2021
Bixiye
P53-21 Update for New-to-Market Medical Drug: aducanumab (Aduhelm)
Taariikhda uu dhaqangalayo barnaamijka: Okt 01, 2021
Bixiye
2021 October Bulletins
Taariikhda uu dhaqangalayo barnaamijka: Okt 01, 2021
Bixiye
P58-21 2022 Renewal Changes Summary for Institutional Providers
Taariikhda uu dhaqangalayo barnaamijka: Okt 01, 2021
Bixiye
Erectile Dysfunction - Phosphodiesterase Type 5 Inhibitors, Topical Prostaglandin - Commercial
Quantity Limit
Taariikhda uu dhaqangalayo Barnaamijka: Nov 01, 2025
Bixiye
Enspryng (satralizumab-mwge) - Medicaid
Prior Authorization, Quantity Limit
Taariikhda uu dhaqangalayo Barnaamijka: 01, Feb 2025
Bixiye
Enspryng (satralizumab-mwge) - Commercial
Prior Authorization, Quantity Limit
Taariikhda uu dhaqangalayo Barnaamijka: 01, Feb 2025